Investors & Media

Dedicated to delivering long-term investment value.

At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.

Press Releases

See All

Updated stock ticker information for uniQure

(Updated every 15 minutes)

Learn More

Security and exchange commission filings for uniQure, including quarterly and annual reports

Learn More

Links to key uniQure corporate governance documents

Learn More

No webcasts scheduled. Check back soon.

September 28, 2023
2023 Cantor Global Healthcare Conference
9:45AM ET - 10:15AM ET
View Webcast
September 6, 2023
Wells Fargo 2023 Healthcare Conference
2:15PM ET-2:50PM ET
View Webcast
June 21, 2023
uniQure Huntington's Disease Program Update: AMT-130
8:30 a.m. ET
View Webcast

See All

Huntington's Disease Program Update AMT-130 – Webcast Presentation
View Presentation
Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements
View Presentation
ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertions
View Presentation
EAHAD 2022 – Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderately Severe Hemophilia B
View Presentation
ESGCT 2022 – linQURE™ platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disorders
View Presentation

See All